Cost estimation of neonatal intensive care in Greece: The case of Athens maternity hospitals

This study aimed to estimate the hospitalisation costs for neonatal intensive care and to investigate any discrepancies with reimbursement by the social funds in Greece. The study was based on a prospective selection of neonates admitted to the intensive care unit of two hospitals within a 3-month period in 2004. Data were collected and classified with respect to birthweight and gestational age. Microcosting recording of data was used. A National Health System hospital perspective was applied. The study sample consisted of 99 neonates with mean cost per infant reaching €5,845 in contrast to the €3,952 reimbursed by the social security funds, showing a discrepancy between actual and norrdnal costs. Cost per infant was found to have an inverse relationship both with birthweight and gestational age. Personnel costs accounted for 59.9% of all resources consumed followed by enteral/parenteral feeding for 16.1% and pharmaceuticals expenses for 11.1%. The remaining covers the costs of consumables, diagnostic test and overheads (12.9%). © 2007 Informa UK Ltd

Generics market in Greece: The pharmaceutical industry's beliefs

The aim of this study was to investigate the beliefs and perspectives of the pharmaceutical industry on generic medication in Greece. Questionnaires were mailed to all 58 members of the Hellenic Association of Pharmaceutical Companies from November 2002 to February 2003. The response rate was 52%, namely 30 questionnaires were completed and returned. The questionnaire requested information on companies' involvement in generics, their opinion on generics' characteristics and on public policies affecting the demand and supply of generic medication. A descriptive analysis of the outcomes, that is percentage comparison through binomial tests and Fisher tests, was performed. According to our findings, 43% of the respondents were involved in the production and distribution of generics and the mean period of their involvement was 12 years. The majority of the respondents were in favor of their companies' involvement in generics, despite the relatively small market share of generics in Greece; 9.7% of total pharmaceutical market in 2003. Bearing in mind that in Greece the promotion of generics is not encouraged, pharmaceutical companies believe that the mandatory introduction of bioequivalence studies is an indirect promotional strategy towards generics. Additionally, the majority declared that their main competitive advantages are their safety, efficacy and effectiveness as well as their economic benefit to the society. Finally, the respondents expressed their preference for the introduction of pharmacoeconomic submissions for drugs' reimbursement by social insurance funds. © 2005 Elsevier Ireland Ltd. All rights reserved